コンテンツへスキップ
Merck

主要文書

すべての文書を表示

573097

WP1066

≥97% (HPLC), STAT3 pathway inhibitor, solid

別名:

STAT3 Inhibitor III, WP1066

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

実験式（ヒル表記法）:
C17H14BrN3O
CAS番号:
857064-38-1
分子量:
356.22
MDL number:
MFCD12912450
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥97% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze, protect from light
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

STAT3 Inhibitor III, WP1066, STAT3 Inhibitor III, WP1066, CAS 857064-38-1, is a cell-permeable AG490 tyrphostin analog that acts as a STAT3 pathway inhibitor. A potent anti-tumor agent.

Quality Level

100

assay

≥97% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

off-white

solubility

DMSO: 10 mg/mL, ethanol: 5 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

Brc1nc(ccc1)\C=C(\C(=O)N[C@@H](C)c2ccccc2)/C#N

InChI

1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1

InChI key

VFUAJMPDXIRPKO-LQELWAHVSA-N

関連するカテゴリー

General description

A cell-permeable AG 490 (Cat. No. 658401 ) tyrphostin analog that acts as an effective STAT3 pathway inhibitor and a much more potent antitumor agent than AG 490 in inhibiting malignant glioma growth both in cultures in vitro (IC50 = 5.6 and 3.7 µM in a viability assay using U87-MG and U373-MG, respectively; no inhibition against nontumor NHA at 10 µM) and in mice in vivo. Shown to cross blood-brain barrier in mice in vivo. Also available in InSolution format (Cat. No. 573129)
A cell-permeable AG 490 (Cat. No. 658401) tyrphostin analog that acts as an effective STAT3 pathway inhibitor and a much more potent antitumor agent than AG 490 in inhibiting malignant glioma growth both in cultures in vitro (IC50 = 5.6 and 3.7 µM in a viability assay using U87-MG and U373-MG, respectively; no inhibition against nontumor NHA at 10 µM) and in mice in vivo. Shown to cross blood-brain barrier in mice in vivo.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
STAT3 pathway
Product does not compete with ATP.
Reversible: no
Target IC50: 5.6 and 3.7 µM in inhibiting malignant glioma growth in a viability assay using U87-MG and U373-MG, respectively

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Iwamaru, A., et al. 2007. Oncogene,26, 2435.





Warning : This material may revert back to its native form.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Irritant (B)

保管分類

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Deleterious substance

pdsc

573097-1.1ML: + 573097-250MG: + 573097-10MG: + 573097-VMG:

jan

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Alicia Haydo et al.
EMBO reports, 24(12), e56964-e56964 (2023-11-08)
Glioblastoma is a very aggressive tumor and represents the most common primary brain malignancy. Key characteristics include its high resistance against conventional treatments, such as radio- and chemotherapy and its diffuse tissue infiltration, preventing complete surgical resection. The analysis of
In-Hye Ham et al.
International journal of oncology, 61(1) (2022-05-28)
The present study aimed to investigate whether the Janus‑activated kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway is a critical mechanism underlying the cancer‑associated fibroblast (CAF)‑induced chemoresistance of gastric cancer (GC). In addition, the present study tried to
Eun-Ji Lim et al.
Cell death & disease, 13(4), 417-417 (2022-04-30)
Colorectal cancer (CRC) has a 5-year survival rate of <10%, as it can metastasize to the lungs and liver. Anticancer drugs and targeted therapies used to treat metastatic colorectal cancer have insufficient therapeutic efficacy and are associated with complications. Therefore
Meng Chi et al.
Annals of translational medicine, 8(8), 531-531 (2020-05-16)
Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor agonist, has been reported to increase the malignancy of breast cancer cells in vitro and stimulate tumor growth in mice. Transmembrane protease serine 2 (TMPRSS2) demonstrates proteolytic activity, resulting in degradation of the
Ahmad Sharanek et al.
Cell reports, 36(9), 109647-109647 (2021-09-02)
Brain tumor stem cells (BTSCs) and intratumoral heterogeneity represent major challenges in glioblastoma therapy. Here, we report that the LGALS1 gene, encoding the carbohydrate binding protein, galectin1, is a key regulator of BTSCs and glioblastoma resistance to therapy. Genetic deletion
関連する文献をすべて表示

関連コンテンツ

Pathways and Biomarkers of JAK/STAT Signaling

Pathways and Biomarkers of JAK/STAT Signaling

An Introduction to Inhibitors and Their Biological Applications - 1st Edition

An Introduction to Inhibitors and Their Biological Applications

JAK/STAT Signaling Research Focus

The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway plays an important role in cell proliferation, cell differentiation, cell migration, and cell death. It is the principal signaling mechanism for a variety of cytokines and growth factors. Constitutive activation or dysregulation of JAK/STAT signaling can result in inflammatory disease, erythrocytosis, gigantism, and leukemia.

グローバルトレードアイテム番号

カタログ番号GTIN
573097-10MGCN04055977266382

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）